Drugs / PLB1004
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06046495 | Jul 2024 → Feb 2028 expected | non-small cell lung carcinoma | Avistone Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05347628 | Aug 2020 → Apr 2023 | non-small cell lung carcinoma | Avistone Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07285148 | Jun 2026 → Dec 2029 expected | non-small cell lung carcinoma | Beijing Pearl Biotechnology Limited Liability Company | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07063329 | Aug 2025 → Mar 2028 expected | non-small cell lung carcinoma | Avistone Pharmaceutical (Ningbo) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06343064 | Jun 2023 → Dec 2026 expected | non-small cell lung carcinoma | Avistone Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07336732 | Mar → Nov 2026 expected | non-small cell lung carcinoma | Avistone Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06574347 | Aug 2024 → Oct 2026 expected | non-small cell lung carcinoma | Avistone Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06015503 | Jul 2023 → Mar 2025 overdue | non-small cell lung carcinoma | Avistone Biotechnology Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06970782 | May 2025 → Dec 2027 expected | non-small cell lung carcinoma | Avistone Biotechnology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06281964 | Dec 2023 → Jun 2028 expected | non-small cell lung carcinoma | Avistone Biotechnology Co., Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLB1004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06574347 ↗ |
| Known as | Andamertinib | “Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations” NCT07336732 ↗ |
| Action | Inhibit | “Oral EGFR Inhibitor PLB1004” NCT06046495 ↗ |
| Modality | Small molecule | “a mono-anilino-pyrimidine compound” NCT06046495 ↗ |
| Route | Oral | “PLB1004 will be orally self-administered by the patient” NCT06046495 ↗ |
| Target | EGFR | “Oral EGFR Inhibitor PLB1004” NCT06046495 ↗ |